Compound research
Semax: Research Overview & Current Status
Semax is a ACTH(4-10) analog / nootropic neuropeptide. Current research status: approved (non-drug / other indication). Semax has been approved and commercially marketed in Russia since 1994 (on the Russian List of Vital & Essential Drugs) for ischemic stroke recovery, cognitive impairment, and certain optic nerve pathologies. It is not approved by the FDA, EMA, or other Western regulators, and most trial evidence comes from Russian-language clinical literature.
Overview
Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from the N-terminal fragment of adrenocorticotropic hormone (ACTH 4-10), engineered to retain neurotrophic and neuroprotective activity without hormonal effects. It has been studied primarily in Russia for cognitive and neurological recovery applications.
ACTH(4-10) analog / nootropic neuropeptide
Research timeline
1980s-1990s
Semax developed at the Russian Academy of Sciences as an ACTH(4-10) analog engineered for nootropic and neuroprotective activity.
Source →1994
Semax approved for clinical use in Russia and added to the Russian List of Vital & Essential Drugs.
Source →2001
Gusev et al. controlled clinical trial reported Semax accelerated neurological recovery in acute ischemic stroke patients.
Source →2000s-2010s
Russian clinical studies reported reduced infarct size, improved neurological scores, and accelerated functional recovery in ischemia models and stroke patients using intranasal Semax.
Source →2010s-2020s
Mechanistic studies identified BDNF/TrkB upregulation in the hippocampus and modulation of serotonergic/dopaminergic signaling as core pathways.
Source →2020s
Emerging preclinical interest in Semax's effects on amyloid-beta aggregation pathways relevant to Alzheimer's disease research, described as an early-stage area with limited data.
Source →
Active & recent research
Semax in acute ischemic stroke recovery
Neurological recovery outcomes and infarct-size reduction with intranasal administration during acute and rehabilitation phases
Semax mechanism of neuroprotection
BDNF/TrkB pathway upregulation, reduced excitotoxicity and oxidative stress in ischemia-reperfusion models
Semax and amyloid-beta pathology
Exploratory investigation of neuroprotective transcriptome modulation relevant to Alzheimer's-related pathways
Key findings
- A 2001 controlled clinical trial by Gusev and colleagues reported that Semax accelerated neurological recovery in patients with acute ischemic stroke, one of the most cited human data points for the compound.
- Multiple Russian clinical and preclinical studies have reported reduced infarct size and improved neurological/motor outcomes with intranasal Semax versus standard care alone, though this literature has not been independently replicated in large Western trials.
- Mechanistic research points to rapid BDNF and TrkB receptor upregulation in the hippocampus as a key driver of Semax's reported neuroprotective and cognitive effects.
- Reviewers note a significant evidence-geography gap: three decades of Semax research exist almost entirely within Russian clinical and pharmacological literature, limiting independent Western verification.
Safety & regulatory notes
Semax is an approved prescription drug in Russia but holds no FDA or EMA approval, meaning it is not a legally marketed drug in the U.S. or EU. Published Russian trial literature reports a favorable tolerability profile with no major adverse effects noted, but this has not been verified through independent Western regulatory review.
We may earn a commission when readers buy through links on this page, at no extra cost to you. Commissions never affect a vendor's score — every vendor is graded on the same public rubric built from published lab documentation, live catalog pricing, and community sentiment. How we score →
Where it's sold for research
We haven't built a dedicated vendor-availability page for Semax yet. See our full research-peptide vendor rankings →
Semax FAQ
Is Semax FDA-approved?+
No. Semax is approved and prescribed in Russia for stroke recovery and cognitive impairment, but it has no FDA or EMA approval and is not a legally marketed drug in the U.S. or EU.
What clinical evidence supports Semax for stroke recovery?+
A 2001 controlled trial by Gusev et al. and subsequent Russian studies reported accelerated neurological recovery and reduced infarct size with intranasal Semax, though this evidence base has not been independently replicated in large Western randomized trials.
What is Semax's proposed mechanism?+
Research points to upregulation of BDNF and its TrkB receptor in the hippocampus, along with modulation of serotonergic and dopaminergic signaling, as the primary mechanisms studied for its neuroprotective and cognitive effects.
Has Semax been studied for Alzheimer's disease?+
There is early, limited mechanistic interest in Semax's effects on amyloid-beta pathways relevant to Alzheimer's research, but sources describe this as an emerging area lacking substantial data, not an established finding.
Sources for this page (3)
Related: all compound research overviews · research radar · full vendor rankings · methodology